Analysts await CymaBay Therapeutics Inc (NASDAQ:CBAY) to reports earnings on March, 16. They expect $-0.35 earnings per share, up 59.77 % or $0.52 from last year’s $-0.87 per share. After $-0.27 actual earnings per share reported by CymaBay Therapeutics Inc for the previous quarter, Wall Street now forecasts 29.63 % negative EPS growth. The stock decreased 0.80% or $0.01 on March 14, hitting $1.24. About 39,775 shares traded hands. CymaBay Therapeutics Inc (NASDAQ:CBAY) has declined 55.99% since August 6, 2015 and is downtrending. It has underperformed by 53.04% the S&P500.
Source: Octa finance